Table 1 |
|||||||||
|
Prevalence of 23 HPV types by collected site among 138 HIV-positive women. Santos, São Paulo, Brazil, 1996–1997 |
|||||||||
|
Site |
|||||||||
|
|
|||||||||
|
Cervix |
Vagina |
Anala |
|||||||
|
|
|||||||||
|
Single |
Multiple |
Total (%) |
Single |
Multiple |
Total (%) |
Single |
Multiple |
Total (%) |
|
|
|
|||||||||
|
HPV - |
53 (38.4) |
47 (34.1) |
37 (36.3) |
||||||
|
HPV + |
50 |
35 |
85 (61.6) |
47 |
44 |
91 (65.9) |
36 |
29 |
65 (63.7) |
|
HR HPV+ |
23 |
28 |
51 (37.0) |
25 |
34 |
59 (42.8) |
16 |
28 |
44 (43.1) |
|
LR HPV+ |
24 |
23 |
47 (34.1) |
19 |
30 |
49 (35.5) |
15 |
20 |
35 (34.3) |
|
|
|||||||||
|
High-risk |
|||||||||
|
16 |
7 |
6 |
13 (9.4) |
6 |
11 |
17 (12.3) |
4 |
5 |
9 (8.8) |
|
18 |
4 |
8 |
12 (8.7) |
4 |
8 |
12 (8.7) |
2 |
10 |
12 (11.8) |
|
31 |
0 |
5 |
5 (3.6) |
1 |
5 |
6 (4.3) |
2 |
1 |
3 (2.9) |
|
33 |
3 |
4 |
7 (5.1) |
1 |
7 |
8 (5.8) |
2 |
4 |
6 (5.9) |
|
39 |
0 |
1 |
1 (0.7) |
1 |
0 |
1 (0.7) |
0 |
1 |
1 (1.0) |
|
45 |
0 |
2 |
2 (1.4) |
0 |
2 |
2 (1.4) |
0 |
1 |
1 (1.0) |
|
52 |
0 |
1 |
1 (0.7) |
0 |
2 |
2 91.4) |
0 |
0 |
0 (0.0) |
|
53 |
5 |
8 |
13 (9.4) |
7 |
8 |
15 (10.9) |
4 |
9 |
13 (12.7) |
|
56 |
1 |
0 |
1 (0.7) |
1 |
1 |
2 (1.4) |
0 |
1 |
1 (1.0) |
|
58 |
1 |
2 |
3 (2.2) |
1 |
2 |
3 (2.2) |
1 |
2 |
3 (2.9) |
|
59 |
1 |
0 |
1 (0.7) |
0 |
0 |
0 (0.0) |
0 |
0 |
0 (0.00 |
|
66 |
0 |
3 |
3 (2.2) |
0 |
3 |
3 (2.2) |
0 |
4 |
4 (3.9) |
|
68 |
1 |
1 |
2 (1.4) |
3 |
1 |
4 (2.9) |
1 |
0 |
1 (1.0) |
|
73 |
0 |
1 |
1 (0.7) |
0 |
1 |
1 (0.7) |
0 |
0 |
0 (0.0) |
|
82 |
0 |
2 |
2 (1.4) |
0 |
2 |
2 (1.4) |
0 |
0 |
0 (0.0) |
|
Subtotal |
23 |
44 |
67 |
25 |
53 |
78 |
16 |
38 |
54 |
|
Low-risk |
|||||||||
|
6 |
3 |
1 |
4 (2.9) |
2 |
2 |
4 (2.9) |
5 |
3 |
8 (7.8) |
|
11 |
3 |
4 |
7 (5.1) |
2 |
5 |
7 (5.1) |
1 |
5 |
6 (5.5) |
|
32 |
0 |
1 |
1 (0.7) |
0 |
1 |
1 (0.7) |
0 |
0 |
0 (0.0) |
|
34 |
1 |
0 |
1 (0.7) |
1 |
0 |
1 (0.7) |
1 |
0 |
1 (1.0) |
|
40 |
0 |
2 |
2 (1.4) |
2 |
2 |
4 (2.9) |
0 |
2 |
2 (1.8) |
|
54 |
1 |
1 |
2 (1.4) |
1 |
2 |
3 (2.2) |
0 |
1 |
1 (1.0) |
|
61 |
4 |
7 |
11 (8.0) |
3 |
8 |
11 (8.0) |
2 |
6 |
8 (7.3) |
|
62 |
0 |
1 |
1 (0.7) |
0 |
1 |
1 (0.7) |
2 |
1 |
3 (2.7) |
|
64 |
0 |
1 |
1 (0.7) |
0 |
0 |
0 (0.0) |
1 |
0 |
1 (1.0) |
|
67 |
2 |
0 |
2 (1.4) |
0 |
1 |
1 (0.7) |
0 |
0 |
0 (0.0) |
|
69 |
2 |
0 |
2 (1.4) |
2 |
1 |
3 (2.2) |
1 |
0 |
1 (1.0) |
|
70 |
1 |
0 |
1 (0.7) |
0 |
1 |
1 (0.7) |
0 |
0 |
0 (0.0) |
|
71 |
2 |
0 |
2 (1.4) |
1 |
1 |
2 (1.4) |
1 |
0 |
1 (1.0) |
|
72 |
0 |
2 |
2 (1.4) |
1 |
3 |
4 (2.9) |
0 |
1 |
1 (1.0) |
|
81 |
2 |
7 |
9 (6.5) |
2 |
9 |
11 (8.0) |
0 |
5 |
5 (4.6) |
|
83 |
2 |
4 |
6 (4.3) |
1 |
3 |
4 (2.9) |
1 |
2 |
3 (2.7) |
|
84 |
1 |
0 |
1 (0.7) |
1 |
0 |
1 (0.7) |
0 |
1 |
1 (1.0) |
|
Subtotal |
24 |
31 |
55 |
19 |
40 |
59 |
15 |
27 |
42 |
|
Unknown |
3 |
10 |
13 (9.4) |
3 |
15 |
18 (13.0) |
5 |
7 |
12 (11.8) |
|
|
|||||||||
|
aPresented for 102 HIV-positive women. HPV = human papillomavirus; HIV = human immunodeficiency virus; HR = High-risk; LR = low-risk |
|||||||||
|
Gonçalves et al. Infectious Agents and Cancer 2008 3:5 doi:10.1186/1750-9378-3-5 |
|||||||||
